Artificial Intelligence for Ulinastatin Responder Outcome & Risk Assessment in CPB

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Artificial Intelligence for Ulinastatin Responder Outcome & Risk Assessment in CPB	Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Shock, Systemic Inflammatory Response Syndrome, multiple organ dysfunction syndrome	Active, not recruiting	Not stated	2026-05-13		NCT07583290

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Anzhen Hospital	149

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Center for Cardiac Surgery and Critical Care	Beijing	China	1

Clinical trials